Chronic Gastritis: a Continuum of Diagnosis and Treatment

Yu.M. Stepanov, I.V. Kushnirenko

Abstract


The article describes the main stages of the development of views on the diagnosis of chronic gastritis with highlighting the issue of diagnosis as an integral part of the set of measures concerning the timely detection of preneoplastic changes in the gastric mucosa. The main views on the development of carcinogenesis are presented based on current knowledge about the factors influencing the course of this process. Among known measures to prevent the development of precancerous changes, today the most important ones are the reliable stratification of risk groups in terms of their development and the strategy for identifying and eliminating Helicobacter pylori as a recognized factor of carcinogenesis. The development of bacterial resistance to basic medications recommended in the schemes of eradication therapy causes a further search of ways to enhance their effectiveness. As shown in a number of studies, the results of which are presented in the article, the most reliable is the inclusion of bismuth subcitrate (De-Nol) in the schemes of eradication.


Keywords


gastritis; classification; Helicobacter pylori; eradication; bismuth subcitrate

References


Correa P. Human Gastric carcinogenesis: A Multistep and Multifactorial Process — First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention / P. Correa // Cancer research. — 1992 Dec 15. — № 52. — P. 6735-6740.

Detection Rate of Helicobacter pylori Against a Background of Atrophic Gastritis and/or Intestinal Metaplasia / Y.J. Youn, K. Nayoung, P.Y. Soo [et al.] // Journal of Clinical Gastroentero­logy. — 2007. — Vol. 41, Is. 8. — Р. 751-755.

Gastric cancer risk in patients with premalignant gastric lesions: a nationwide cohort study in the Netherlands / de Vries A. C., van Grieken N. C., Looman C.W. [et al.] // Gastroenterology. — 2008. — № 134. — Р. 945-952.

Helicobacter pylori-negative Gastritis in Erosive Esophagitis, Nonerosive Reflux Disease or Functional Dyspepsia Patients / Peura D.A., Haber M.M., Hunt B. [et al.] // Journal of Clinical Gastroenterology. — 2010. — Vol. 44, Is. 3. — Р. 180-185.

Stolte M. The updated Sydney system: Classification and grading of gastritis as the basis of diagnosis and treatment / M. Stolte, A. Mei // Can. J. Gastroenterol. — 2001. — Vol. 15, № 9. — P. 591-598.

Sipponen P. The Sydney System for classification of gastritis 20 years ago / P. Sipponen, A.B. Price // Journal of Gastroenterology and Hepatology. — 2011. — № 26, Suppl. 1. — Р. 31-34.

Incidence of gastric cancer among patients with gastric precancerous lesions: observational cohort study in a low risk Western population // H. Song, I. G. Ekheden, Z. Zheng [et al.] // BMJ. — 2015. — Р. 351-357.

Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994 / Dixon M.F., Genta R.M., Yardley J.H. [et al.] // Am. J. Surg. Pathol. — 1996. — № 20 (10). — Р. 1161-1181.

OLGA staging for gastritis: A tutorial / M. Rugge, P. Correa, F.Di Mario [et al.] // Digestive and Liver Disease. — 2008. — № 40. — Р. 650-658.

Gastritis: The histology report / M. Rugge, G. Pennelli, E. Pilozzi [et al.] // Digestive and Liver Disease. — 2011. — № 43S. — Р. 373-384.

Gastritis OLGA-staging and gastric cancer risk: a twelve-year clinico-pathological follow-up study / Rugge M., De Boni M., Pennelli G. [et al.] // Alimentary Pharmacology and Therapeutics. — 2010. — № 31. — P. 1104-1111.

The staging of gastritis with the OLGA system by using intestinal metaplasia as an accurate alternative for atrophic gastritis / L.G. Capelle, A.C. de Vries, J. Haringsma [et al.] // Gastrointestinal endoscopy. — 2010. — Vol. 71, № 7 — P. 1150-1158.

Operative link for gastritis assessment vs operative link on intestinal metaplasia assessment / M. Rugge, M. Fassan, M. Pizzi [et al.] // World Journal of Gastroenterology. — 2011. — № 17 (41). — P. 4596-4661

First-degree relatives of patients with early-onset gastric carcinoma show even at young ages a high prevalence of advanced OLGA/OLGIM stages and dysplasia / R. Marcos-Pinto, F. Carneiro, M. Dinis-Ribeiro [et al.] // Alimentary Pharmacology and Therapeutics. — 2012. — № 35 (12). — Р. 1451-1459.

Gastritis staging: interobserver agreement by applying OLGA and OLGIM systems / Sergejs Isajevs, Inta Liepniece-Karele, Dainius Janciauskas [et al.] // Virchows Arch. — Springer-Verlag Berlin Heidelberg, 2014. — 5 p.

Staging of intestinal- and diffuse-type gastric cancers with the OLGA and OLGIM staging systems / S.-J. Cho, I.J. Choi, M.-C. Kook [et al.] // Aliment Pharmacol Ther. — 2013. — № 38 (10). — Р. 1292-1302.

Impact of the angulus biopsy for the detection of gastric preneoplastic conditions and gastric cancer risk assessment / M. Varbanova, T. Wex, D. Jechorek [et al.] // J. Clin. Pathol. — 2015. — Рublished online.

The correlation of endoscopic and histological diagnosis of gastric atrophy / Eshmuratov A., Nah J.C., Kim N. [et al.] // Dig. Dis. Sci. — 2010. — 55 (5). — Р. 1364-1375.

Yoon H., Kim N. Diagnosis and Menegment of High Risk Group for Gastric Cancer // Gut and Liver. — 2015. — Vol. 1, № 9. — P. 5-17.

Diagnosis of Gastritis — Review from Early Pathological Evaluation to Present Day Management / I.L. Szabo, K. Cseko, J. Czimmer [et al.] // Current Topics in Gastritis — 2012. — 19 p.

Saka A., Yagi K., Nimura S. OLGA- and OLGIM-based staging of gastritis using narrow-band imaging magnifying endo­scopy // Dig. Endosc. — 2015. — № 27 (7). — Р. 734-741.

OLGA and OLGIM stage distribution according to age and Helicobacter pylori status in the Korean population. / Nam J.H., Choi I.J., Kook M.C. [et al.] // Helicobacter. — 2014. — № 19 (2). — P. 81-89.

Helicobacter pylori Infection on Levels of DNA Damage in Gastric Epithelial Cells / S.M. Everett, K.L.M. White, I.M. Drake [et al.] // Helicobacter. — 2002. — № 7. — Р. 271-280.

Helicobacter pylori cagA and vacA genotypes as predictors of progression of gastric preneoplastic lesions: a long-term follow-up in a high-risk area in Spain / C.A. Gonzalez, C. Figueiredo, C.B. Lic [et al.] // Am. J. Gastroenterol. — 2011. — № 106. — Р. 867-874.

Analysis of cagA in Helicobacter pylori strains from Colombian populations with contrasting gastric cancer risk reveals a biomarker for disease severity / J.T. Loh, C.L. Shaffer, M.B. Piazuelo [et al.] // Cancer Epidemiol. Biomarkers. Prev. — 2011. — № 20. — Р. 2237-2249.

Correa P. The gastric precancerous cascade / P. Correa, M.B. Piazuelo // J. Dig. Dis. — 2012. — № 13 (1). — Р. 2-9.

Association between cagA and vacA genotypes and pathogenesis in a Helicobacter pylori infected population from South-eastern Sweden / Karlsson A., Ryberg A., Dehnoei M.N. [et al.] // BMC Microbiol. — 2012. — № 2 (12). — Р. 129.

Correlation of Helicobacter pylori genotypes with gastric histopathology in the central region of a South-European country / Almeida N., Donato M.M., Romãozinho J.M. [et al.] // Dig. Dis. Sci. — 2015. — № 60 (1). — Р. 74-85.

Toll-Like Receptors as Biomarkers of Gastric Carcinogenesis: Implications for Diagnosis, Prognosis and Treatment / P. Pimentel-Nunes, J.B. Soares, M. Dinis-Ribeiro // Journal of Cancer Therapy. — 2013. — № 4. — Р. 1037-1047.

Zabaleta J. Multifactorial etiology of gastric cancer / J. Zabaleta // Methods Mol. Biol. — 2012. — № 863. — Р. 411-435.

Shiotani A. Eradication of gastric cancer is now both possible and practical / Shiotani A., Cen P., Graham D.Y. // Semin. Cancer Biol. — 2013. — № 23. — Р. 492-501.

Tepes B. Population based Helicobacter pylori screening and eradication: advances versus side effects / B. Tepes // Curr. Pharm. Des. — 2014. — № 20 (28). — Р. 4501-4509.

Mégraud F. The challenge of Helicobacter pylori resistance to antibiotics: the comeback of bismuth-based quadruple therapy / F. Mégraud // Therap. Adv. Gastroenterol. — 2012. — № 5 (2). — Р. 103-109.

Cytoprotective effect of bismuth subsalicylate in indome­thacin-treated rats is associated with enhanced mucus bismuth concentration / Tanaka S., Guth P.H., Carryl O.R. [et al.] // Aliment. Pharmacol. Ther. — 1997. — № 11 (3). — Р. 605-612.

Evaluation of effects of ethyl alcohol and bismuth subsalicylate on gastric mucosal barrier in man / Dy R.M., Lof J., DiBaise J.K. [et al.] // Dig. Dis. Sci. — 1999. — № 44 (2). — Р. 286-289.

Gastroduodenal mucosal prostaglandin generation in patients with Helicobacter pylori before and after treatment with bismuth subsalicylate / Avunduk C., Suliman M., Gang D. [et al.] // Dig. Dis. Sci. — 1991. — № 36 (4). — Р. 431-434.

Evidence that bismuth salts reduce invasion of epithelial cells by enteroinvasive bacteria / Gump D.W., Nadeau O.W., Hendricks G.M. [et al.] // Med. Microbiol. Immunol. — 1992. — № 181 (3). — Р. 131-143.

Manhart M.D. In vitro antimicrobial activity of bismuth subsalicylate and other bismuth salts / M.D. Manhart // Rev. Infect. Dis. — 1990. — № 12, Suppl. 1. — Р. 11-15.

Sox T.E. Binding and killing of bacteria by bismuth subsalicylate / Sox T.E., Olson C.A. // Antimicrob. Agents Chemo­ther. — 1989. — № 33 (12). — Р. 2075-2082.

Lee S.P. The mode of action of colloidal bismuth subcitrate / S.P. Lee // Scand. J. Gastroenterol. — 1991. — № 185. — Р. 1-6.

Chronic erosive gastritis — a therapeutic approach with bismuth / Malfertheiner P., Stanescu A., Baczako K. [et al.] // Scand. J. Gastroenterol. — 1988. — № 142. — Р. 87-92.

Wagstaff A.J. Colloidal bismuth subcitrate. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in peptic ulcer disease / Wagstaff A.J., Benfield P., Monk J.P. // Drugs. — 1988. — № 36 (2). — Р. 132-157.

Lambert J.R. The actions of bismuth in the treatment of Helicobacter pylori infection / Lambert J.R., Midolo P. // Aliment. Pharmacol Ther. — 1997. — № 11, Suppl. 1. — Р. 27-33.

High cure rate of Helicobacter pylori infection using tripotassium dicitrato bismuthate, furazolidone andclarithromycin triple therapy for 1 week / Xiao S.D., Liu W.Z., Hu P.J. [et al.] // Aliment. Pharmacol. Ther. — 1999. — № 13 (3). — Р. 311-315.

Laine L. Is it time for quadruple therapy to be first line? / L. Laine // Can. J. Gastroenterol. — 2003. — № 17, Suppl. B. — Р. 33-35.

Seven-Day Bismuth-based Quadruple Therapy as an Initial Treatment for Helicobacter pylori Infection in a High Metronidazole Resistant Area / Vilaichone R.K., Prapitpaiboon H., Gamnarai P. [et al.] // Asian Pac. J. Cancer Prev. — 2015. — № 16 (14). — Р. 6089-6092.

Current Status of Five Different Regimens for Empiric First-Line Helicobacter pylori Eradication in Turkey / Gungor G., Baglıcakoglu M., Kayacetin E. [et al.] // Digestion. — 2015. — № 92 (2). — Р. 55-59.

Efficacy of Clarithromycin Containing Bismuth-Based Re­gimen as a Second-Line Therapy in Helicobacter pylori Eradication / Mokhtare M., Agah S., Fakheri H. [et al.] // Middle East J. Dig. Dis. — 2015. — № 7 (2). — Р. 75-81.

Prapitpaiboon H., Mahachai V., Vilaichone R. K. High Efficacy of Levofloxacin-Dexlansoprazole-Based Quadruple Therapy as a First Line Treatment for Helicobacter pylori Eradication in Thailand // Asian Pac. J. Cancer Prev. — 2015. — № 16 (10). — Р. 4353-4356.

A comparison between sequential therapy and a modified bismuth-based quadruple therapy for Helicobacter pylori eradication in Iran: a randomized clinical trial / Fakheri H., Taghvaei T., Hosseini V. [et al.] // Helicobacter. — 2012. — № 17 (1). — Р. 43-48.

Bismuth-based first-line therapy for Helicobacter pylori eradication in type 2 diabetes mellitus patients. Demir M., Göktürk S., Oztürk N. A. [et al.] // Digestion. — 2010. — № 82 (1). — Р. 47-53.

The efficacy of bismuth containing quadruple therapy as a first-line treatment option for Helicobacter pylori / Uygun A., Kadayifci A., Safali M. [et al.] // J. Dig. Dis. — 2007. — № 8 (4). — Р. 211-215.

Efficacy of bismuth-based triple therapy in children with abdominal pain and Helicobacter pylori gastritis / Shamaly H., Berkowitz D., Rosenthal E. [et al.] // J. Pediatr. Gastroenterol. Nutr. — 2000. — № 30 (2). — Р. 198-200.

High efficacy of 14-day triple therapy-based, bismuth-containing quadruple therapy for initial Helicobacter pylori eradication / Sun Q., Liang X., Zheng Q. [et al.] // Helicobacter. — 2010. — № 15 (3). — Р. 233-238.

Optimum duration of regimens for Helicobacter pylori eradication / Yuan Y., Ford A. C., Khan K. J. [et al.] // Cochrane Database Syst. Rev. — 2013.

Malfertheiner P. Bismuth Improves PPI-based Triple Therapy for H. Pylori Eradication / P. Malfertheiner // Nature reviews. Gastroenterology & Hepatology. — 2010. — Vol. 7. — P. 538-539.

Management of precancerous conditions and lesion in the stomach (MADS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter study group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED) / M. Dinis-Ribeiro, M. Areia, A.C. de Vries [et al.] // Endoscopy. — 2012. — № 44. — P. 74-94.




DOI: https://doi.org/10.22141/2308-2097.4.58.2015.81588

Refbacks

  • There are currently no refbacks.


Copyright (c) 2016 GASTROENTEROLOGY

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© Publishing House Zaslavsky, 1997-2017

 

 Яндекс.МетрикаSeo анализ сайта Рейтинг@Mail.ru